{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T08:07:58Z","timestamp":1782634078617,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.anai.2025.06.022","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T10:17:44Z","timestamp":1750587464000},"page":"425-433.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6549","authenticated-orcid":false,"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weily","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Boguniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Bennike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.anai.2025.06.022_bib0001","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","article-title":"Comorbidities and the impact of atopic dermatitis","volume":"123","author":"Silverberg","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2025.06.022_bib0002","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","article-title":"Comorbidities of atopic dermatitis-what does the evidence say?","volume":"151","author":"Thyssen","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2025.06.022_bib0003","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jaad.2022.01.009","article-title":"American Academy of Dermatology Guidelines: awareness of comorbidities associated with atopic dermatitis in adults","volume":"86","author":"Davis","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.anai.2025.06.022_bib0004","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2025.06.022_bib0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.anai.2021.02.026","article-title":"Rhinitis prevalence and association with atopic dermatitis: a systematic review and meta-analysis","volume":"127","author":"Knudgaard","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2025.06.022_bib0006","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/19458924221090050","article-title":"Chronic rhinosinusitis and the increased incidence of atopic dermatitis","volume":"36","author":"Son","year":"2022","journal-title":"Am J Rhinol Allergy"},{"issue":"2","key":"10.1016\/j.anai.2025.06.022_bib0007","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","article-title":"Real-world prevalence of prurigo Nodularis and burden of associated diseases","volume":"140","author":"Huang","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"suppl 64","key":"10.1016\/j.anai.2025.06.022_bib0008","first-page":"232","article-title":"Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis","volume":"56","author":"Khan","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2025.06.022_bib0009","series-title":"StatPearls","article-title":"Atopy","author":"Justiz Vaillant","year":"2024"},{"issue":"1","key":"10.1016\/j.anai.2025.06.022_bib0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2025.06.022_bib0011","series-title":"Allergy in Practice","first-page":"6","author":"Ring","year":"2005"},{"issue":"5","key":"10.1016\/j.anai.2025.06.022_bib0012","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jaci.2023.01.019","article-title":"Biomarkers in atopic dermatitis","volume":"151","author":"Bakker","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2025.06.022_bib0013","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/all.16108","article-title":"Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years","volume":"79","author":"Guttman-Yassky","year":"2024","journal-title":"Allergy"},{"issue":"12","key":"10.1016\/j.anai.2025.06.022_bib0014","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/ng.3985","article-title":"Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology","volume":"49","author":"Ferreira","year":"2017","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.anai.2025.06.022_bib0015","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jaad.2020.02.055","article-title":"Prevalence of asthma in patients with atopic dermatitis: a systematic review and meta-analysis","volume":"84","author":"Ravnborg","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2025.06.022_bib0016","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/jdv.18919","article-title":"Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge-proven food allergy: a systematic review and meta-analysis","volume":"37","author":"Christensen","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"23","key":"10.1016\/j.anai.2025.06.022_bib0017","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations","volume":"132","author":"Chu","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2025.06.022_bib0018","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.anai.2018.07.042","article-title":"Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.06.022_bib0019","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jaad.2021.07.064","article-title":"Phenotypes of atopic dermatitis and the risk for subsequent asthma: a systematic review and meta-analysis","volume":"86","author":"Li","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2025.06.022_bib0020","series-title":"ADBRY\u00ae (Tralokinumab-Idrm) Injection for Subcutaneous Use [Prescribing Information]","year":"2023"},{"issue":"6","key":"10.1016\/j.anai.2025.06.022_bib0021","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the Phase 3 ECZTRA 6 randomized clinical trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2025.06.022_bib0022","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2025.06.022_bib0023","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2025.06.022_bib0024","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjd.21867","article-title":"Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials","volume":"187","author":"Simpson","year":"2022","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2025.06.022_bib0025","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2217\/imt-2017-0191","article-title":"Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program","volume":"10","author":"Panettieri","year":"2018","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.anai.2025.06.022_bib0026","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jaci.2023.01.001","article-title":"Might biologics serve to interrupt the atopic march?","volume":"151","author":"Spergel","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.anai.2025.06.022_bib0027","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.anai.2025.06.022_bib0028","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.anai.2025.06.022_bib0029","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1080\/19466315.2023.2268313","article-title":"Covariate-adaptive biased coin randomization for master protocols with multiple interventions and biomarker-stratified allocation","volume":"16","author":"Song","year":"2024","journal-title":"Stat Biopharm Res"},{"issue":"24","key":"10.1016\/j.anai.2025.06.022_bib0030","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-yearly Depemokimab in severe asthma with an eosinophilic phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.anai.2025.06.022_bib0031","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/j.jaip.2019.05.030","article-title":"The safety and efficacy of anti-IL-13 treatment with tralokinumab (CAT-354) in moderate to severe asthma: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2025.06.022_bib0032","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jaad.2020.11.037","article-title":"Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: a systematic review and meta-analysis","volume":"85","author":"Ravn","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2025.06.022_bib0033","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40257-020-00577-1","article-title":"Conjunctivitis in dupilumab clinical trials for adolescents with atopic dermatitis or asthma","volume":"22","author":"Bansal","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2025.06.022_bib0034","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjd.20810","article-title":"Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials","volume":"186","author":"Wollenberg","year":"2022","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2025.06.022_bib0035","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2025.06.022_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2019.100080","article-title":"IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper","volume":"13","author":"Ansotegui","year":"2020","journal-title":"World Allergy Organ J"},{"issue":"4","key":"10.1016\/j.anai.2025.06.022_bib0037","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221104","article-title":"Targeting type 2 immunity and the future of food allergy treatment","volume":"220","author":"Berin","year":"2023","journal-title":"J Exp Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625003151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625003151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:13:39Z","timestamp":1759299219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120625003151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1081120625003151"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.06.022","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}